Literature DB >> 6606048

Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation.

B Teisner, I Brandslund, N Grunnet, L K Hansen, J Thellesen, S E Svehag.   

Abstract

A patient experienced an anaphylactoid shock after receiving a transfusion with 5-10 ml of leucocyte-depleted blood. Complement measurements revealed pronounced elevation of split products of the third complement factor (C3c and C3d), normal but fluctuating levels of native C3, significantly decreased levels of C4, normal factor B concentrations and low levels of factor B split products. The results indicate complement activation via the classical pathway as a causative mechanism of the anaphylactoid shock, and suggest an antigen-antibody reaction as the etiological factor. The nature of the antigen-antibody reaction initiating the complement activation could not be established. The disappearance rate (T/2) of C3d from the plasma after the acute C-activation was measured to approximately 4 hr, and the half life of C3c was significantly shorter.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606048

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  16 in total

Review 1.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  Microparticles in stored red blood cells as potential mediators of transfusion complications.

Authors:  Wenche Jy; Marco Ricci; Sherry Shariatmadar; Orlando Gomez-Marin; Lawrence H Horstman; Yeon S Ahn
Journal:  Transfusion       Date:  2011-04       Impact factor: 3.157

3.  Defining the complement biomarker profile of C3 glomerulopathy.

Authors:  Yuzhou Zhang; Carla M Nester; Bertha Martin; Mikkel-Ole Skjoedt; Nicole C Meyer; Dingwu Shao; Nicolò Borsa; Yaseelan Palarasah; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

4.  Production of Staphylococcal Complement Inhibitor (SCIN) and Other Immune Modulators during the Early Stages of Staphylococcus aureus Biofilm Formation in a Mammalian Cell Culture Medium.

Authors:  Andi R Sultan; Jasper W Swierstra; Nicole A Lemmens-den Toom; Susan V Snijders; Silvie Hansenová Maňásková; Annelies Verbon; Willem J B van Wamel
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

5.  Three cases of factor I deficiency: the effect of treatment with plasma.

Authors:  J Møller Rasmussen; B Teisner; H H Jepsen; S E Svehag; F Knudsen; H Kirstein; M Buhl
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

6.  Complement receptor expression and activation of the complement cascade on B lymphocytes from patients with systemic lupus erythematosus (SLE).

Authors:  H V Marquart; A Svendsen; J M Rasmussen; C H Nielsen; P Junker; S E Svehag; R G Leslie
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

7.  Complement Deposition on the Surface of RBC After Trauma Serves a Biomarker of Moderate Trauma Severity: A Prospective Study.

Authors:  Abhigyan Satyam; Kostas Andreo; Peter H Lapchak; Jurandir J Dalle Lucca; Roger B Davis; Maria G Tsokos; Nathan I Shapiro; George C Tsokos
Journal:  Shock       Date:  2020-01       Impact factor: 3.533

8.  Differential immunological profiles herald magnetic resonance imaging-defined perioperative cerebral infarction.

Authors:  Jonathon P Fanning; Louise E See Hoe; Margaret R Passmore; Adrian G Barnett; Barbara E Rolfe; Jonathan E Millar; Allan J Wesley; Jacky Suen; John F Fraser
Journal:  Ther Adv Neurol Disord       Date:  2018-03-13       Impact factor: 6.570

Review 9.  Complement diagnostics: concepts, indications, and practical guidelines.

Authors:  Bo Nilsson; Kristina Nilsson Ekdahl
Journal:  Clin Dev Immunol       Date:  2012-11-14

10.  Development of a C3c-based ELISA method for the determination of anti-complementary potency of Bupleurum polysaccharides.

Authors:  Mulu Wu; Hong Li; Yunyi Zhang; Daofeng Chen
Journal:  Acta Pharm Sin B       Date:  2015-04-07       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.